NETHERLANDS – Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has sealed a US$586 million, three-target agreement with Macrogenics…
Read MoreTag: biobucks
J&J’s biotech unit, Janssen inks antibody-drug conjugate deal with Mersana
USA – Mersana Therapeutics Inc has announced a research collaboration and license agreement with Janssen Biotech Inc, a subsidiary of Johnson & Johnson, to discover antibody-drug conjugates (ADCs) for three…
Read More